Willow active extract of the bark, called salicin, was isolated to its crystalline form in 1828 by Henri Leroux, a French pharmacist, and Raffaele Piria, an Italian chemist, who then succeeded in separating out the compound in its pure state. In 1897, Felix Hoffmann created a synthetically altered version of salicin (in his case derived from the "Spiraea" plant), which caused less digestive upset than pure salicylic acid. The new drug, formally acetylsalicylic acid, was named Aspirin by Hoffmann's employer Bayer AG. This gave rise to the hugely important class of drugs known as nonsteroidal anti-inflammatory drugs (NSAIDs). Some of humans'
Ethyl eicosapentaenoic acid Ethyl eicosapentaenoic acid Ethyl eicosapentaenoic acid (E-EPA, icosapent ethyl) is a derivative of the omega-3 fatty acid eicosapentaenoic acid (EPA) that is used in combination with changes in diet to lower triglyceride levels in adults with severe (≥ 500 mg/dL) hypertriglyceridemia. This was the second class of fish oil-based drug to be approved for use as a drug and was approved by the FDA in 2012. These fish oil drugs are similar to fish oil dietary supplements but the ingredients are better controlled and have been tested in clinical trials. The company that developed this drug, Amarin Corporation, challenged the